Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PTLA - Portola Pharmaceuticals Inc.

Previous close
18.03
0   0%

Share volume: 0
Last Updated: Wed 01 Jul 2020 06:00:00 AM CEST
Pharmaceuticals: Other: 0%

PREVIOUS CLOSE
CHG
CHG%
$18.03
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 37%
Liquidity 48%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$18.03
P/E Ratio 
N/A
DAY RANGE
$18.03 - $18.03
EPS 
-$3.77
52 WEEK RANGE
$5.31 - $31.73
52 WEEK CHANGE
-$31.91
MARKET CAP 
1.403 B
YIELD 
N/A
SHARES OUTSTANDING 
77.819 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$77,525,078
AVERAGE 10 VOLUME 
$2,318,233
AVERAGE 30 VOLUME 
$2,335,645
Company detail
CEO:
Region: US
Website: http://www.portola.com
Employees: 408
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceuticals: Other
Sector: Health Technology

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Recent news